Chiesi USA - Boston, MA
posted 3 months ago
The Sr. Manager, Strategy & Business Knowledge for Rare Diseases at Chiesi will play a pivotal role in shaping the strategic direction of the Global Rare Diseases (GRD) business unit. This position is integral to the evaluation of long-term strategic initiatives and the development of the therapeutic area strategic plan. The manager will be responsible for conducting comprehensive analyses that encompass both organic and inorganic growth opportunities, collaborating closely with various functions within the organization to ensure alignment with corporate goals. The role requires a deep understanding of the pharmaceutical landscape, particularly in the rare disease sector, and the ability to synthesize complex data into actionable insights. In this role, the manager will support the refinement of the GRD strategic plan, contributing to both qualitative and quantitative aspects that will inform the long-term profit and loss (P&L) projections for the therapeutic area. This includes working with the Global Pipeline Strategy Team to align strategies and provide data-driven recommendations for strategic initiatives. The manager will also be tasked with evaluating potential partnerships, acquisitions, and licensing opportunities, coordinating cross-functional teams to assess the financial viability and strategic fit of these opportunities. This involves preparing Net Present Value (NPV) models and conducting scenario analyses to evaluate various business outcomes. Additionally, the Sr. Manager will foster collaboration across departments, including finance, legal, operations, and business development, to ensure effective communication and alignment on strategic initiatives. The role requires the ability to prepare reports and presentations for executive leadership, clearly communicating findings and insights to relevant stakeholders. The manager will also be expected to proactively identify and suggest inorganic growth opportunities, staying informed about the latest trends in the pharmaceutical industry, particularly in the rare disease space.